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Summary 
Prior studies using polyclonal populations of natural killer (NK) cells have revealed that expression 
of certain major histocompatibility complex (MHC) class I molecules on the membrane of normal 
and transformed hematopoietic target cells can prevent NK cell-mediated cytotoxicity. However, 
the extent of clonal heterogeneity within the NK cell population and the effect of self versus 
non-self MHC alleles has not been clearly established. In the present study, we have generated 
more than 200 independently derived human NK cell clones from four individuals of known 
human histocompatibility leukocyte antigens (HLA) type. NK clones were analyzed for cytolytic 
activity against MHC class I-deficient Epstein Barr virus (EBV) transformed B lymphoblastoid 
cell lines (B-LCL) stably transfected with several HLA-A,  -B, or -C genes representing either 
self or non-self alleles. All NK clones killed the prototypic HLA-negative erythroleukemia K562 
and most lysed the MHC class  I-deficient C1R and 721.221 B-LCL. Analysis of the panel of 
HLA-A, -B, and -C transfectants supported the following general conclusions. (a) Whereas recent 
studies have suggested that HLA-C antigens may be preferentially recognized by NK cells, our 
findings indicate that 70% or more of all NK clones are able to recognize certain HLA-B alleles 
and many also recognize HLA-A alleles. Moreover, a single NK clone has the potential to recognize 
multiple alleles of HLA-A, HLA-B, and HLA-C antigens. Thus, HLA-C is not unique in conferring 
protection against NK lysis.  (b) No simple patterns of HLA specificity emerged. Examination 
of a large number of NK clones from a single donor revealed overlapping, yet distinct, patterns 
of reactivity when a suffldently broad panel of HLA transfectants was examined. (c) Both autologous 
and allogeneic HLA antigens were recognized by NK clones. There was neither evidence for 
deletion of NK clones reactive with self alleles  nor any indication for an increased frequency 
of NK clones recognizing self alleles.  (d) With only a few exceptions, protection conferred by 
transfection of HLA alleles  into B-LCL was usually not absolute.  Rather a continuum from 
essentially no protection for certain alleles (HLA-A*0201) to very striking protection for other 
alleles  (HLA-B*5801),  with a wide range of intermediate effects, was observed.  (e) Whereas 
most NK clones retained a relatively stable HLA specificity, some NK clones demonstrated variable 
and heterogeneous activity over time. (J) NK cell recognition and specificity cannot be explained 
entirely by the presence or absence of HLA class I antigens on the target cell. For example, HLA- 
B'5801, an allele that strongly protected two different B-LCL targets, had no effect on NK cell 
susceptibility when expressed in two NK sensitive tumor targets, K562 and Jurkat. These results 
suggest the possibility that NK cells may possess cytotoxic mechanisms that are both MHC 
dependent and MHC  independent, depending on the nature of the target cell. 
H 
uman  NK  cells  are  defined  as  membrane  CD3-, 
CD16 +,  and/or  CD56 +  lymphocytes  (1).  NK  cells 
have the ability to lyse certain tumor cells and virus-infected 
cells and to secrete cytokines after stimulation (2). Tradition- 
ally, NK cell-mediated cytotoxicity has been defined as non- 
major MHC-restricted  killing in that NK cells are capable 
of lysing both autologous and allogeneic tumor cell targets 
(3). However, an association exists between levels of NK sen- 
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tain target cells.  For many NK-sensitive targets, predomi- 
nantly those of lymphoid origin, there is an inverse correlation 
between class I expression and susceptibility to NK cell-medi- 
ated cytotysis (4). Ljunggren and ~rre (5) have demonstrated 
that H-2 class I-deficient variants derived from routine lym- 
phoma cell lines (EL-4 and RBL-5) were rejected  by syngeneic 
animals, whereas, the wild-type MHC class I-bearing lym- 
phomas were highly tumorigenic. This response was NK cell 
dependent and could be abrogated by the depletion of host 
NK cells (5, 6). Similarly, in vitro cytotoxicity assays showed 
that the MHC class I-deficient variants were more sensitive 
to NK ceil lysis than the wild-type cells. In additional studies, 
up regulation of MHC class I on tumor ceUs by IFN-3/treat- 
ment was accompanied by a decreased susceptibility to NK 
call-mediated cytotoxicity (7). 
Formal proof that susceptibility to NK cell-mediated cy- 
totoxicity is affected by expression of MHC class I on target 
ceils has been provided using molecular genetic techniques. 
Transfection of MHC class I genes into class I-deficient call 
lines rendered these targets relatively resistant to NK cell- 
mediated lysis. Storkus and co-workers (8-10) have demon- 
strated that transfection of certain MHC class I alleles into 
ClP,, an HLA-deficient EBV-transformed B lymphoblastoid 
cell line (B-LCL), 1 rendered this cell line resistant to lysis by 
freshly isolated, polyclonal peripheral blood NK call popula- 
tions.  Of particular  note,  only certain HLA  aUeles were 
protective, whereas others and all the murine MHC class I 
molecules tested (H2-K  b DP or  L d) were ineffective (8,  9). 
Shimizu and DeMurs (11) similarly demonstrated that trans- 
fection of HLA genes into 721.221,  a class I-negative EBV 
transformed B-LCL, resulted in reduced susceptibility to NK 
cell-mediated lysis. Likewise, when murine YAC-1 and EL4 
cells were transfected with ~2 microglobulin or H-2, the in- 
creased expression of H-2 was accompanied by a decrease in 
NK cell lysis (12-14).  In these and other studies a correlation 
existed between the level of class I expression at the ceil surface 
and the degree of protection from NK cell lysis. A threshold 
level of class I expression may therefore be required for pro- 
tection to be observed (7, 9, 11). The property of MHC class 
I expression to render cells resistant to NK cell-mediated lysis 
has recently been extended to normal, nontransformed he- 
matopoietic cells. Normal lymphoblasts from mice homozy- 
gous for disrupted/3z-microglobulin genes are susceptible to 
lysis by NK cells from wild-type or heterozygous littermates 
(15, 16). Moreover, bone marrow grafts from the ~2-micro- 
globulin-deficient mice are rejected by radioresistant NK cells 
in normal, syngeneic recipients (17). 
Whereas expression of MHC class I molecules can cer- 
tainly affect susceptibility to NK cell-mediated lysis, under- 
standing of the specificity of the MHC recognition or of the 
mechanism of this process is limited. In this study, we have 
generated a large panel of human NK cell clones from donors 
1 Abbreviations used in  this paper: ADCC, antibody-dependent  cellular 
cytotoxidty; B-LCL, B lymphoblastoid  cell lines. 
of known MHC type and tested these effector cells for lysis 
of MHC class 1-deficient EBV transformed B-LCL and other 
NK-sensitive cell lines transfected with either self- or non- 
self alleles of different MHC class I loci. This approach has 
provided new insights into the clonal heterogeneity of NK 
cells and has demonstrated that both MHC-dependent and 
MHC-independent modes of target cell recognition exist. 
Materials  and Methods 
Preparation of  NK Cells and NK Clones.  Mononuclear cells from 
peripheral blood of healthy adults were isolated by standard Ficoll- 
Hypaque techniques. For cloning of NK cells, PBL were stained 
with PE-conjugated anti-CD56 mAb and FITC-conjugated anti- 
CD3 mAb. Membrane (m)CD3-,CD56 § NK cells were cloned 
at 1 cell per well using a single cell deposition system of the FAC- 
Star  pLUs flow cytometer  (Becton Dickinson  Immunocytometry 
Systems, San Jose, CA). Clones were established  using culture con- 
ditions described previously (18). All clones generated by this pro- 
cedure were mCD3-,CD56 +, and mediated NK cytolytic func- 
tion. The HLA type of the NK clones are summarized in Table 
t. NK cell clones established from fetal liver or thymus (19) were 
generously provided by Dr. Maria Jos6 S~chez (DNAX). 
Antibodies.  Anti-CD3 (anti-Leu 4), CD16 (anti-Leu 11a), and 
CD56 (anti-Leu 19) were generously provided by Becton Dickinson 
Immunocytometry Systems. mAb MA2.1 reacts with HLA-A*0201, 
HLA-B*5701 and HLA-B*5801 (20, 21). 362.7 is a murine IgG1 
mAb directed against a monomorphic determinant on human HLA- 
A,B,C molecules that was generated by immunizing BALB/c mice 
with human NK cells and fusing immune splenocytes  with Sp2/0 
myeloma cells. 
Immunofluorescence and Flow Cytometry.  Ceils  were stained with 
fluorochrome-conjugated  mAb for detection of cell surface  antigens 
by immunofluorescence, as described (22). Appropriate purified or 
fluorochrome-conjugated, isotype-matched control Ig were used 
in all experiments.  Samples  were analyzed  using a FACScan  |  (Becton 
Dickinson). 
Cell-mediated Cytotoxicity.  Cytotoxic activity was measured in 
a 4-h SlCr-radioisotope  release assay (23). Antibody-dependent cel- 
lular cytotoxicity (ADCC) was performed as described previously 
(24). For ADCC, targets were coated with saturating amounts of 
polyclonal rabbit  antiserum  against human hematopoietic ceils 
(raised against K562 membranes), generously provided by Dr. John 
Ortaldo (National Cancer Institute,  Frederick, MD). 
Target Cell  Panel.  The  NK-sensitive, HLA-negative  K562 
erythroleukemia ceil line was purchased from American Type Cul- 
ture Collection (Rockville, MD). The Jurkat T leukemia cell line 
(HLA-A9, -A25, -B7, -B41) was generously provided by Dr. Art 
Weiss (University of California, San Francisco, CA). CIR B-LCL 
(HLA-A-,B*35031~  §  (25, 26)  was provided by Dr. 
Peter Cresswell (Yale  University, New Haven, CT) and the 721.221 
B-LCL (HLA-A-,B-,C-) (27) was generously provided by Dr. 
Robert DeMurs (University of Wisconsin, Madison, WI). Trans- 
fectants of 721.221 and C1R used in this study are summarized 
in Table 1 (10, 21,  25-33).  C1R transfectants were generously 
provided by Drs. Peter Cresswell (Yale University), Jeffrey Dawson 
(Duke University, Durham, NC), Victor Engelhard (University 
of Virginia, Charlottesville, VA) and Paul Leibson (Mayo Clinic, 
Rochester, MN). 721.221.B'5101 and 721.221.Cw*0301 were gener- 
ously provided by Dr. Robert DeMurs (University of Wisconsin, 
Madison, WI) (33, 34). 
PCR  and  Transfection.  RNA  was  isolated  as  described by 
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pared in a 40-/A reaction volume containing 50 mM Tris-HCl, pH 
8.3,  50 mM KCI, 10 mM MgCI~, 1 mM dithiothreitol,  1 mM 
EDTA, 0.1/~g/ml BSA, 1 mM dNTPs, 2 mM spermidine, 70 U 
RNAsin (Promega, Madison, WI), 0.4 mM Na pyrophosphate, 
10 U AMV reverse transcriptase (Pharmacia, Hscataway, NJ), and 
10/~g of total RNA. The reaction mixture was incubated at 42~ 
After 45 min, RNA was hydrolyzed  by adding 40/A 0.3 N NaOH, 
30 mM EDTA, and boiling for 5 min. cDNA was phenol/chloro- 
form extracted and ethanol precipitated. PCR. reactions were per- 
formed (43 cycles  at 94~  1 min; 55~  1 min; 72~  1 min) using 
a GeneAmp Kit (Perkin-Elmer Corp., Norwalk, CT). Primers for 
generation  of HLA-B*5801 cDNA  were:  GGGCCTCGAGG- 
GACTCAGAATCTCCCCAGACGCCGAG  (sense) and  CCG- 
CAAGCTTCTGGGGAGGAAACACAGGTCAGCATGGGAAC 
(anti-sense). The PCK product was subcloned into the pBJl-neo 
expression vector (36). B-LCL andJurkat cells  were transfected  with 
HLA-B*5801-pBJl-neo by dectroporation, drug selected, and cells 
with high-density ceU surface antigen expression were sorted by 
flow cytometry, as described previously (37). 
HLA Typing.  HLA class I typing was kindly performed by Dr. 
David Eckels  and Ms. Susan Hackbarth (The Blood Center of South- 
eastern Wisconsin, Milwaukee, WI) using a standard microlym- 
phocytotoxicity assay. 
Results 
Clonal Heterogeneity  of  NK Cell Recognition of  MItC.  Prior 
studies have reported that freshly isolated, polyclonal popu- 
lations of NK cells lyse HLA class I-deficient EBV trans- 
formed B-LCL and that transfection with certain HLA class 
I  genes can protect the target (8-11,  38).  Such analysis  of 
polydonal populations however, would not reveal NK cell 
donal heterogeneity or specificity. We have therefore, estab- 
lished an extensive pand of NK call clones (Table 1) to inves- 
tigate this question. 
NK clones were established from single mCD3-,CD56 + 
lymphocytes, which were isolated by flow cytometry from 
the peripheral blood of adult donors. The target cell panel 
(Table  2)  consisted of the parental  C1R  cell line  (HLA- 
A-,B*3503 I~  Cw*0401 +) (9, 26), C1R transfected with 
HLA-A*  0101, -A'0201, -A'0301, -A*  6801, -A*  6901, -B* 0702, 
-B'2705, -B'3701, and -B'5801, the 721.221 cell line (HLA- 
A-,B-,C-)  (11, 39)  and  721.221  transfected with  HLA- 
B'5101,  -B'5801,  and-Cw*0301. 
All of the transfectants expressed substantial levels of MHC 
class I (Fig.  1). Although some variation of expression be- 
tween targets was observed, comparable levels of expression 
have been previously reported to confer resistance to NK cell 
lysis (8-10,  38). The levels of dass I  expression were rou- 
tinely monitored by flow cytometry throughout the course 
of the study and only transfectants with stable  surface an- 
tigen expression were analyzed. 
To demonstrate that the HLA-transfected targets were sus- 
ceptible to cell-mediated cytotoxicity, they were coated with 
a heterologous rabbit anti-human leukocyte antiserum and 
assayed for susceptibility to ADCC using freshly isolated NK 
cells and selected NK cell clones as effectors. All targets were 
equally susceptible to ADCC, demonstrating >60% specific 
lysis at an effector/target cell ratio of 6:1 in a 4-h SlCr ra- 
dioisotope release assay (not shown). 
Initial experiments were carried out with two NK cell 
clones, designated NK10 and NK11, which have been main- 
tained in culture for extended periods (>2 yr). Both clones 
mediate high levels of lysis against K562, C1R and 721.221. 
Although these two clones were generated from the same 
donor and have the same NK cell phenotype (mCD3-,- 
CD16 + ,CD56 +) they display differential abilities to lyse the 
HLA-transfected targets (Fig. 2). Two targets, CIR.B*5801 
and .221.Cw*0301, were protected from lysis by NKll (Fig. 2 
B). The lysis of other targets (CltL.A'0101,  C1R.A*6901, 
C1R.B*2705,  C1R.B*3701, and .221.B'5101) was only slightly 
decreased compared to that of the parental C1R and 721.221 
cell lines. NK10 displayed a different specificity of HLA pro- 
tection: CL1LA*0101, C1R.B*0702, CIR.B*2705,  C1K.B*3701, 
C1R.B*5801,  .221.B'5101  and .221.Cw*0301  targets were 
refractory to lysis (Fig. 2 A). These results indicate that simi- 
larly derived NK cell clones from the same individual mediate 
different interactions with MHC class I gene products. More- 
over, the findings with clone NK10 clearly demonstrate that 
a single NK clone can potentially recognize HLA-A, HLA-B, 
and HLA-C antigens. 
The killing by NK10 and NK11 of B-LCL and HLA trans- 
fectants was examined over a broad effector to target ratio 
(not shown). As high levels of killing were seen in the range 
of 6:1 and 3:1 (E/T ratios), these ratios were used for the 
remainder of the study. The overall pattern ofHLA spedfidty 
for NK10 and NKll  was reproducible. 
It should be appreciated that the relative levels of lysis of 
the HLA-transfected targets varied from high levels of lysis 
to complete resistance.  To simplify the analysis, we consid- 
Table  1.  HLA Class I Typing of NK Cell Clones 
Donor  Designation  of clones  HLA class I serotype 
287  NK287 
288  NK288 
315  NK315 
186  NK186 
1147  NK10,  NK11 
Three sources  Fetal clones 
A30,  B14,  B47,  (W4/W6),  Cw8 
A25,  B18,  B51,  (W4/W6),  Cw-- 
A2,  A3,  B7, B62, (W6), Cw3, Cw7 
A2,  A3, B7, B58, Cw3, Cw7 
A2,  A3, B7, (W6), Cw7 
ND 
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Target 
designation  Name 
Parental cell 
HLA expression  Type 
Transfected DNA (28) 
HLA 
allele  Ref 
K562  K562 
K562.B*5801  K562 
CIR  C1R 
CIR.A*0101  CIR 
CIR.A*0201  C1R 
C1R.A*0301  CIR 
C1R.A*6801  C1R 
CIR.A*6901  CIR 
CIR.B*0702  CIR 
CIR.B*2705  CIR 
CIR.B*3701  CIR 
C1R.B*5801  C1R 
721.221  721.221 
.221.B'5101  721.221 
.221 .Cw*0301  721.221 
721.221  721.221 
.B'5801 
JURKAT  JURKAT 
JURKAT  JURKAT 
.B'5801 
A- 
A- 
A- 
A- 
A- 
A- 
A- 
A- 
A- 
A- 
A-, B-, C- 
A-, B-, C- 
B'3503 low  Cw*0401 + 
B'3503 ~w  Cw*0401 + 
B'3503 low  Cw*0401 + 
B'3503 low  Cw*0401 + 
B'3503 low  Cw*0401 § 
B'3503 low  Cw*0401 + 
B'3503 low  Cw*0401 § 
B'3503 jo~  Cw*0401 § 
B'3503 low  Cw*0401 + 
B'3503 lo~  Cw*0401 + 
A-, B-, C- 
A-, B-, C- 
A-, B-, C- 
A-, B-, C- 
A9, A25, B7, B41 
A9, A25, B7, B41 
None 
cDNA 
None 
Genomic 
Genomlc 
Genomic 
Genomlc 
Genomic 
Genomlc 
Genomlc 
Genomlc 
Genomlc 
None 
Genomic 
Genomic 
cDNA 
None 
cDNA 
B'5801 
A*0101 
A*0201 
A*0301 
A'6801 
A'6901 
B*0702 
B'2705 
B'3701 
B'5801 
B'5101 
Cw*0301 
B'5801 
B'5801 
21 
25,26 
29 
30 
30 
31 
10,32 
21 
27 
33 
34 
21 
21 
" DNA clone generated in the laboratory of Peter Cresswell, Yale University. 
* DNA clone generated in the laboratory of Elliot Cowan, National Institutes of Health. 
ered the HLA-transfected targets to be "protected" from or 
refractory to NK cell-mediated cytolysis if lysis was 50% or 
less than that obtained with the untransfected parental cell. 
This criterion ensures  that only substantial levels of protec- 
tion are considered significant. 
The observation that two NK clones generated from the 
same donor differentially  lysed the panel of HLA-transfected 
target cells suggested that clonal heterogeneity exists within 
the NK cells of an individual. To further examine this possi- 
bility, a  large number  of mCD3- ,CD16 +/- ,CD56 +  NK 
cell clones were generated from four donors of different HLA 
type (Table 1). All NK clones possessed cytolytic ability, as 
demonstrated by their ability to kill K562 cells. 71%  (221 
of 313) of the clones generated also displayed lytic capacity 
against the parental MHC class I-deficient C1R and 721.221 
targets. NK clones able to lyse C1R or 721.221 at a level of 
30% or greater were further tested for the ability to lyse the 
panel of HLA-transfected targets. A high percentage of the 
total clones tested were unresponsive against targets trans- 
fected with  HLA-B  alleles,  in  particular  B'3701  (51%), 
B'5801  (71%)  and B'5101  (49%)  (Table 3).  A  lesser per- 
centage (18-35%) of clones were unresponsive against HLA- 
Cw*0301, -A*0101, and -A*0301 transfected targets. How- 
ever, only a small percentage (2-6%) of clones were prevented 
from lysing the A*0201, A'6801, and A'6901 transfectants. 
Therefore, in general, HLA-B alleles appear to be more pro- 
tective than HLA-A alleles. Of the HLA alleles tested, B'5801, 
B'3701, and B'5101 protected target cells from NK lysis with 
the highest frequency. 
These results were obtained using NK clones derived from 
adult peripheral blood. We have recently reported that func- 
tional NK cells arise early during human fetal ontogeny, being 
detectable from 6 wk gestation until birth (19). To deter- 
mine whether HLA class I recognition is operative in fetal 
NK cell populations, NK clones derived from fetal liver or 
thymus were tested for the ability to lyse the HLA-transfected 
target cells. The results obtained with NK clones generated 
from three fetuses were pooled and are represented in Table 
3. Like the adult NK clones, all fetal NK clones lysed K562 
and most killed CIR and 721.221. Moreover, as with adult 
NK  clones,  HLA-B*3701,  -B'5801,  and  -B'5101  alleles 
provided protection against a high percentage (42-59%) of 
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CIR.A*6901 
C1 R.B*5801 
A) NK10 
100 
u)  8O 
60 
U. 
,o 
20 
.221 .Cw*0301 
Figure  1.  HLA expression on target cell panel. Calls were stained with 
FlTC-conjugated anti-HLA chss l-specific mAb 362.7 (open histograms) 
or FITC-conjugated  isotype-specific  control mAb (shaded  histograms).  X-axis, 
4 decade log fluorescence; y-axis, relative number of cells. A slight shift 
was observed when 721.221 was stained with 362.7. This is most likely 
due to nonspecific  binding as we were unable to immunoprecipitate  MHC 
class I molecules from az~l-labeled  cells using either 362.7 or W6/32 mAb. 
the  fetal  NK clones with  other  aUdes being less efficient. 
Thus, fetal NK cells behaved similarly to adult NK cells with 
regard  to HLA class  I  recognition. 
Do Self HLA Alleles Protect the Target Cell from NK Cell 
Lysis?  Since the donors used to generate the NK clones in 
these studies were of known HLA type, it was possible to 
B) NK11 
100 
80 
,-I 
60 
O_ 
I,L 
40 
W  0,. 
20 
0  ¸ 
555555555  ~. 
Figure  2.  Lysis  of HLA  +  \- target cells by NK10 and NK11. Two NK 
clones were tested for the ability to lyse MHC class I-deficient cell lines 
(K562, C1R, 721.221) and HLA-transfected targets in a 4-h slCr release 
assay. A and B show percent specific lysis for NK10 and NK11, respec- 
tively. The effector/target ratio (E:T) was 6:1. 
Table  3.  Percentage  of NK Clones Tested which Show Decreased Lytic Potential against Target Cells Transfected with Different 
MHC Class I Alleles 
CIR.  CIR.  CIR.  CIR.  C1R.  CIR.  C1R.  C1R.  C1R.  .221.  .221. 
Donor  A*0101  A*0201  A*0301  A'6801  A'6901  B*0702  B'2705  B'3701  B'5801  B'5101  Cw*0301 
287  ND  0%  6 (32)  0  (32)  ND  6  (32)  50 (32)  31  (32)  47 (32)  44 (32)  22 (32) 
(n  =  32)* 
288  ND  3  (38)  47 (38)  26 (38)  ND  71  (38)  0  (38)  92 (38)  89 (38)  47 (38)  16  (38) 
315  42  (62)  5 (62)  19 (62)  0  (62)  6  (62)  10 (62)  39 (62)  61  (62)  82 (62)  55  (62)  48 (62) 
186  ND  ND  ND  ND  ND  4  (26)  25 (16)  4  (26)  73 (26)  37 (16)  23 (26) 
Fetal*  19  (27)  0  (59)  5 (59)  0  (59)  4  (27)  20 (59)  5 (59)  42 (59)  59  (59)  49 (59)  36 (59) 
Total  35  (89)  2 (191)  18 (191)  5  (191)  6 (89)  22 (217)  23  (207)  51  (217)  71  (217)  49 (207)  33  (217) 
* The percentage of NK clones which showed decreased iysis towards CIR or 721.221 HLA transfectants compared with the parental cells is indicat- 
ed. The NK clone was considered to be "less lytic" against the HLA-transfected target if the percent cytotoxicity was 50% or less than that of 
the parental cell. In each case the NK specific lysis of the parental C1R or 721.221 targets was )30%.  The absolute number of clones included 
in this analysis is shown in parenthesis. Alleles that represent self alleles for donors 288, 315, and 186 are underlined. 
t NK clones derived from three fetuses (liver or thymic tissue). 
1325  Litwin et al. address the issue of whether self HLA alleles expressed on 
the target cell would preferentially protect a target from lysis. 
When the HLA phenotype of the donors (Table 1) and the 
HLA specificity of the NK clones (Table 3) were compared, 
no obvious correlation was found. Most of the HLA alleles 
that  provided  the  strongest protection  against  NK  cell- 
mediated lysis (e.g., HLA-B*5101, -B'3701,  and -B'5801) 
were allogeneic. Moreover, transfectants expressing certain 
self alleles were infrequently protected.  These observations 
indicate that self (HLA-matched) alleles do not preferentially 
protect a target cell from lysis by NK clones. For example, 
the phenotype of donor 315 is HLA-A2, -A3,  -B7, -B62, 
-Cw3, -Cw7. These antigens, with the exception of B62 and 
Cw7, were represented in the target cell panel. Of the self 
alleles tested, only Cw*0301 prevented NK cell lysis by a sub- 
stantial number of the clones derived from donor 315, whereas 
several non-self alleles (e.g., B'5101,  B'5801,  and B'3701) 
were protective for most clones. A*0301 and B*0702, which 
are self alleles for the 315 NK cell clones, prevented lysis by 
only a minority of the NK clones. By contrast,  these alleles 
were protective for many of the clones from the HLA dis- 
parate donor 288. 
An EBV-transformed B-LCL was generated from donor 
315 and NK clones from this donor were tested for cytotox- 
icity against the autologous cell line. Of 22 NK clones exam- 
ined, none demonstrated substantial cytotoxicity against the 
autologous B-LCL. The autologous B-LCL presumably ex- 
presses all of the self HLA-A,B,  and C antigens. Therefore, 
the presence of multiple self HLA antigens on normal autol- 
ogous cells may provide complete resistance to NK clone lysis. 
HLA-B*3701,  -B'5801,  and -B'5101 protected target cells 
from lysis by 50-70% of all clones tested, yet these alleles 
did not match the HLA type of donors 287, 288, or 315. 
Moreover, the levels of  protection were the greatest with the 
transfectants expressing these alleles. In many cases, protec- 
tion was  almost  complete.  This protection is not due to 
nonspecific resistance to lysis as the HLA-B*3701, -B'5801, 
and -B'5101 transfectants were susceptible to ADCC medi- 
ated by these NK cell clones (data not shown). 
Since HLA-B*5801 was observed to confer the most con- 
sistent and strongest  protection when NK clones from al- 
logeneic donors were tested, we examined whether B'5801 
would also demonstrate such a profound effect using NK 
clones from a donor expressing this allele. NK clones were 
prepared from donor 186 and were tested for cytotoxicity 
against the target cell panel (Table 3). Note that the HLA 
type of this donor was identical to donor 315, with excep- 
tion that donor 186 expressed HLA-B58 rather than HLA- 
B62 (Table 1). Similar to the results obtained with the donors 
287, 288, and 315, HLA-B*5801 conferred protection to the 
B-LCL transfectants against 73%  (19 of 26) of donor 186 
NK clones. Therefore, irrespective of whether HLA-B*5801 
is autologous or allogeneic, a high frequency of NK clones 
recognize this specificity. 
Although there was no evidence for "fine specificity" of 
MHC recognition, NK clones from the four donors showed 
differential abilities to lyse the HLA-transfected target cells 
(Table 3). For example, 50% of the clones generated from 
donor 287 and 39% of those from donor 315 were unable 
to lyse the C1R.B*2705  target, whereas all of the clones 
from donor 288 were lytic against this target. 47 and 71% 
of the 288 clones were unable to kill the C1R.A*0301 and 
C1R.B*0702  targets, respectively. Conversely, most of the 
NK clones from donors 287 and 315 lysed these targets. In 
conclusion, NK clones from different individuals demonstrate 
different patterns of HLA specificity. However, there was no 
requirement for the HLA to be a self allele to mediate pro- 
tection and frequently non-self  alleles were more potent than 
self alleles in conferring target resistance. Additionally, there 
was no evidence for clonal deletion of NK clones reactive 
with self HLA alleles or any particular increase in frequency 
of NK clones reactive with self HLA alleles. 
Are there Recognizable Subsets of  NK Cells?  Given the het- 
erogeneity  observed between NK clones derived from a single 
individual, we examined whether distinct subsets of NK clones 
could be identified on the basis of FILA preference. Of the 
59 NK clones established from donor 315 that were able to 
lyse C1R or 721.221, a broad spectrum of clonal heteroge- 
neity was evident in their reactions with the HLA transfec- 
tants (Table 4). It is evident that the NK clones established 
from a single individual and cultured under identical condi- 
tions were remarkably heterogeneous with respect to inter- 
action with the HLA transfectants. Although the majority 
of the clones were unresponsive to targets expressing HLA- 
B'3701, -B'5801,  and -B'5101, no simple patterns of HLA 
specificity emerge. Many clones demonstrated overlapping, 
yet distinct, patterns of reactivity when a sufficiently broad 
panel of HLA transfectants was examined. Moreover, note 
that in many cases a single NK done had the ability to recog- 
nize multiple HLA-A,-B,  and -C alleles. 
To illustrate the individual behavior of the NK clones, cy- 
totoxicity of representative clones from donor 315  against 
the HLA class I transfectant target cell panel is presented in 
Fig. 3. Clones NK 315.17 and NK 315.37 were unresponsive 
to only one HLA-transfected  target each, CIR.B*5801  and 
.221.Cw*0301, respectively. By contrast,  clone NK 315.33 
was refractory to both C1R.B*3701 and C1R.B*5801 (Fig. 
3, A, B, and C). Reduced levels of lysis by clone NK 315.41 
were observed with all HLA-transfected targets (Fig. 3 D). 
The other clones shown in the Fig. 3 exemplify other dis- 
tinct patterns of NK clonal heterogeneity. 
A substantial proportion of  human NK cells express CD8cx 
(23, 40), a receptor for MHC class I molecules expressed on 
MHC class I-restricted T cells (41, 42). NK clones from donor 
315 were examined for CD8cr expression by flow cytometry 
and 15% of these NK clones expressed  CD8cx. However, both 
the CD8cr + and the CDSol-  NK clones displayed similar 
HLA specificities (data not shown). 
Will HLA-B*5801 Protect other Target Cells from NK Cell 
Lysis?  HLA-B*5801 was noteworthy as this gene protected 
the C1R target cells from lysis by the majority of the NK 
clones and erdaibited  the strongest degree of  protection. There- 
fore, we investigated whether this HLA allele would also ex- 
hibit protection when expressed in other cell types. To this 
1326  NK and HLA Recognition I
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1328  NK and HLA Recognition end, HLA-B*5801 cDNA was prepared from the WT49 EBV 
B-LCL by PCR and was cloned into the pBJl-neo expres- 
sion vector. WT49 is the line from which the genomic B'5801 
DNA was obtained and used to transfect the CIR cell line 
(21).  The HLA-negative 721.221 B-LCL, the NK-sensitive 
Jurkat T leukemia cell line, and the HLA-negative erythro- 
leukemia K562 were transfected with HLA-B*5801-pBJl-neo. 
Cells expressing HLA-B*5801 were selected by flow cytom- 
etry using mAb MA2.1 that reacts with HLA-B*5801. Sig- 
nificant expression of HLA-B*5801 was achieved in theJurkat 
and 721.221 cell lines; lower expression levels were obtained 
in the K562 cells (Fig. 4). Jurkat T cells express endogenous 
HLA-A9, -A25, -B7, -B41, but the mAb MA2.1 used to se- 
lect for HLA-B*5801 transfectants does not react with these 
alleles. 
Additional NK clones were generated from donor 315 and 
tested for cytolytic activity against  the target  cell panel as 
well as 721.221 transfected with B'5801 (not shown). In these 
experiments, all NK clones lysed K562 and 89% of the clones 
generated were lytic (>30% specific lysis) against CIK and 
721.221. Consistent with the previous cloning from this donor 
(see Table 2), the HLA-B alleles, B'5101, B'3701, and B'5801, 
protected the targets from lysis by most of the clones. 52% 
of the clones failed to lyse the HLA-Cw*0301  transfected 
targets. Using this series of NK clones, none of the HLA-A 
alleles tested in this assay (A*0201, A'6801, A'6901) protected 
the transfectants  from NK lysis. 
When lysis of C1R.B*5801  and 721.221.B'5801  by the 
series of NK clones was compared, most clones (13 of 19, 
68%)  that  failed to lyse CIK.B*5801  also did not kill the 
721.221.B'5801 transfectant. However, certain clones demon- 
strated differential behavior against these transfectants.  For 
example, clones NK 315.B6 and NK 315.B10 efficiently lysed 
721.221.B'5801,  but not C1R.B*5801  (Table 5).  C1K ex- 
presses endogenous HLA-Cw*0401 and a low level ofB'3503 
(26), whereas 721.221 is class  I HLA negative.  It is there- 
fore conceivable that  the NK clones inhibited from lysing 
C1K.B*5801, but not 721.221.B'5801, require a cooperation 
of B'5801  and either Cw*0401 or B'3503 for target pro- 
tection. Two clones (NK 315.B4 and NK 315.A9) efficiently 
lysed K562 and 721.221 and were less responsive to 721.221.- 
B'5801 (Table 5); however, neither clone lysed C1K. Thus, 
it  is possible that  these clones  can be inhibited by either 
Cw*0401  or B'5801. 
Selected NK 315 clones that were unable to lyse CIR.B*5801 
or 721.221.B'5801 targets were retested in a subsequent ex- 
periment that also included K562.B*5801 andJurkat.B*5801 
transfectants as targets.  Again, most of the clones were un- 
responsive to both CIR.B*5801 and 721.221.B'5801.  Note 
that  transfection  of CIR with  HLA-B*5801 conferred es- 
sentially complete resistance against certain NK clones (e.g., 
NK 315.A16) (Table 5).  By contrast,  transfection of K562 
or Jurkat  with  HLA-B*5801  never protected these targets 
from NK cell-mediated lysis. HLA-B*5801 was also unable 
to protect Jurkat or K562 targets against lysis by donor 186 
NK dones where HLA-B58 is a self antigen  (not shown). 
Therefore, certain tumor targets which are very sensitive to 
NK cell lysis cannot be protected by the expression of an HLA 
allele which is strongly protective when expressed in other 
cell types. Note that Jurkat.B* 5801 expresses levels of HLA- 
B'5801 comparable to other HLA transfectants (i.e., CIR.- 
B'3701 or .221.Cw*0301) which are refractory to NK cell 
Table  5.  Lysis of Various Cell Types Transfected with HLA-B*5801 
K562.  C1R.  C1K.  721.221.  JURKAT. 
Clone  K562  B'5801  C1R  B'3701  B'5801  721.221  B'5801  JUKKAT  B'5801 
315.A5  71  64  49  6  1  68  23  68  63 
315.A6  67  64  82  57  1  78  28  79  65 
315.A14  72  69  53  10  2  55  0  77  69 
315.A16  80  87  100  30  0  78  6  75  66 
315.A17  71  70  75  29  0  81  5  78  59 
315.A22  62  66  76  14  0  85  8  68  57 
315.B13  75  75  65  22  0  74  2  73  68 
315.B4  70  72  2  0  5  58  36  48  53 
315.B1  68  76  35  5  3  100  0  63  70 
315.B6  72  75  89  10  25  82  80  79  73 
315.B8  66  75  76  6  4  75  8  66  61 
315.B10  71  77  86  17  0  76  43  73  75 
315.A9  100  82  9  0  2  74  7  80  76 
Values for the percent specific lysis by NK 315 clones against parental cells and HLA-B*3701 and -B'5801 transfectants, are shown. Numbers in 
underlined, boldface denote "protection" from NK cell lysis as described in Table 3. 
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K562 
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JURKAT 
KS62.B*5801 
JURKAT,  B*5801 
Figure 4.  Expression  of HLA-B*5801 on 721.221, K562, and Jurkat 
transfectants. 721.221 and K562 transfectants were stained with FITC- 
conjugated anti-HLA class l-spedfic  mAb 362.7 (open histograms)  or FITC- 
conjugated isotype-specific  control mAb (shaded histograms).  Jurkat cells 
were stained with mAb MA2.1 (open histograms)  or isotype-matched  con- 
trol Ig (shaded  histograms),  followed  by FITC conjugated goat anti-mouse 
Ig. X-axis, 4 decade log fluorescence;  y-axis, relative number of cells. The 
slight staining of K562 with 362.7 is most likely nonspecific  due to FcR 
binding as K562 cells are known to express high levels of FcR. Attempts 
have been made to obtain K562 with higher levels of HLA-B*5801 ex- 
pression, but without success. Expression of HLA on the HLA-B*  5801 
K562 transfectant has been confirmed by immunoprecipitation of HLA 
from 12SI-surface-labeled  cells using the MA2.1 mAb (not shown). 
lysis. Although only low levels of HLA-B*5801 were expressed 
on K562 transfectants,  there was no evidence of any HLA- 
conferred protection against this target in three separate assays. 
Prior studies using B-LCL as targets have indicated that re- 
sistance to NK lysis correlated with  the surface density of 
HLA, but that even low levels of HLA expression conferred 
detectable protection  (10). 
Do NK Cells Maintain a Stable HLA Specificity Over Time? 
48 NK clones were assayed in three experiments  (over the 
course of a month) to determine if the HLA specificities  of 
the clones would remain stable with time. NK clones were 
established from two donors and were cultured using iden- 
tical conditions.  In summary, 35 of 48 NK clones retained 
a qualitatively similar pattern of HLA specificity during the 
three assays. However, in most cases variation was observed 
with one to three of the nine targets tested. Four of 48 NK 
clones differed greatly on each assay date.  Whereas nine of 
1330  NK and HLA Recognition 
the clones lost lytic potential over time, they maintained the 
same pattern of HLA specificity.  Interestingly, seven clones 
lost the ability to kill C1R, 721.221,  and the HLA transfec- 
tants, yet remained lytic against K562, suggesting different 
mechanisms of recognition or lysis of these cell types. Data 
from eight NK clones representing the different types of be- 
havior observed are shown in Fig.  5. 
MHC-indetxon~t Recognition of Targets by NK Cells.  Where- 
as MHC class I antigens can certainly influence recognition 
by most NK clones, some clones displayed a lytic capability 
which  was  apparently  independent  of this  phenomenon. 
Clones NK 287.A15 and NK 287.A19 exhibit strong lysis 
of K562; however, none of the remaining targets, including 
the HLA-negative 721.221 cell lines, were lysed at significant 
levels (<20%) (Fig. 6, A  and B). By contrast, NK 288.B26 
and NK 287.A25 displayed ubiquitous cytotoxicity (Fig. 6, 
C and D). In each case, the percent specific lysis was >50% 
and none of the HLA-transfected targets were significantly 
refractory to NK cell-mediated cytolysis. Obviously since all 
HLA alleles were not tested, it is possible that these NK clones 
may be regulated by other alleles.  However, together with 
the observation that  transfection of Jurkat and K562 with 
HLA-B*5801 failed to affect target cell recognition and lysis, 
these findings also support the notion that NK clones may 
disregard either the lack of or presence of MHC class I on 
certain  target  cells. 
Discussion 
The mechanisms by which natural NK cells recognize sus- 
ceptible targets remains elusive. ~  et al. (6) have proposed 
that NK cells recognize cells lacking self MHC class I mole- 
cules. According to this "missing self" hypothesis, NK cells 
possess receptors for self MHC that when engaged transmit 
a "negative" signal that  prevents initiation  of cytolytic ac- 
tivity ("negative signal" model).  An alternative possibility 
is that  expression of MHC class I molecules on the target 
cell  sterically  prevents  interaction  with  "target  antigen" 
receptors on the NK cells ("target masking" model). Presently, 
most data support the former mechanism (43, 44). Karlhofer 
et al.  (43) have identified a membrane glycoprotein, Ly49, 
expressed on a subset of routine NK cells in C57BL/6 mice 
that apparently is a receptor for H-2D  a and inhibits Ly49 + 
NK cells from killing target cells expressing H-2D  a. Trans- 
fection of H-2D  a into tumor cell lines lacking this allele has 
formally demonstrated  that  Ly49 + NK cells are inhibited 
from killing targets expressing polymorphic MHC class I mol- 
ecules, indicating that interaction between Ly49 and H-2D  a 
conveys a dominant negative signal (43). A family of Ly49- 
related genes have been identified in mice (45), providing the 
possibility  for  at  least  a  restricted  repertoire  of NK  cell 
specificity. In humans, receptors for polymorphic MHC class 
I molecules have not as yet been identified, although Moretta 
et al. (46) have described mAbs against two NK cell-associated 
antigens that appear to correlate with the ability of NK cell 
clones to lyse allogeneic lymphoblasts. 
Studies of signal transduction events in NK cells lends ad- 
ditional  support to the negative signal model. Kaufrnan et %
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Figure 6.  NK clones which only lysed 
K562 and NK clones which showed ubiq- 
uitous cytolytic activity. A and B show the 
cytotoxicity  data for two NK dories which 
only have lytic potential against K562.  C 
and D  show two clones which have high 
lytic potential against all targets in  the 
panel. Assay conditions were as described 
in Fig. 2 legend. 
al. (44) found no differences in the early signal transduction 
events (i.e.,  phosphoinositide hydrolysis and Ca  2+  flux) in 
NK cell binding of either C1R or HLA class I-transfected 
CIR. These early signaling events are known to occur when 
NK cells bind NK susceptible but not NK-resistant targets 
(47-50); therefore, Kaufman et al. (44) argue that class I ex- 
pression on target cells does not mask a specific receptor in- 
teraction, but rather initiates inhibitory signals which do not 
alter early signaling events. 
Analysis of the heterogeneity of NK cell recognition at 
the clonal level in mice has been hindered by the inability 
to generate NK cell clones. The cloning of human NK cells 
has provided an opportunity to explore the extent of hetero- 
geneity in HLA recognition within the NK cell population. 
In the present study we established a large series of NK clones 
from four different individuals and tested these effector cells 
for interaction with HLA class I-deficient B-LCL transfected 
with several HLA alleles. Several conclusions were derived 
from these experiments. First, clonal heterogeneity was ob- 
served when NK clones from a single donor were assayed 
against this large target cell panel and differences existed be- 
tween different individuals with respect to which HLA al- 
Ides provided protection. Whereas all NK clones lysed K562, 
demonstrating their cytolytic potential, there was consider- 
able variability in lysis of the HLA class I-deficient B-LCL 
and HLA transfectants. However, no "fine" specificity of HLA 
recognition was evident. In general, the patterns of protec- 
tion observed with the various HLA transfectants indicated 
that several alleles were capable of mediating inhibition of 
lysis by a single NK clone. Moreover, a single NK clone was 
able to recognize multiple alleles of HLA-A,-B, and -C. These 
results imply that either only a few receptors for HLA dass 
I exist on NK cells that broadly cross react with multiple 
alleles or alternatively, that a single NK clone may express 
many receptors for MHC with distinct specificities. Resolu- 
tion of this question awaits identification of these receptors. 
Our results are compatible with the possibility that specific 
structures may exist on NK cells which are involved in rec- 
ognition of MHC class I gene products. If this indeed proves 
to be the case, our data suggest that these recognition struc- 
tures are heterogeneously expressed and perhaps differentially 
regulated. 
Another conclusion from these experiments is that the pro- 
tection conferred by MHC class I on the target is usually 
1332  NK and HLA Recognition not absolute. With only a few exceptions, expression of the 
MHC alleles in the transfectants reduced levels of cytolysis 
only partially. While we arbitrarily designated >50% reduc- 
tion of lysis as the criteria for HLA protection of a target, 
it is noteworthy that many alldes provided lesser degrees of 
inhibition. Overall, the levels of protection observed repre- 
sent a continuum from essentially no protection for certain 
alleles (e.g., IqLA-A*0201) to very striking protection for other 
alleles (e.g., HLA-B*5801), with a wide range of intermediate 
effects. These results are in contrast to the dominant nega- 
tive signal observed when Ly49 + NK cells interacted with 
H-2D d bearing cells (43).  Furthermore, using human NK 
clones as effectors the HLA transfectants demonstrating pro- 
tection could be readily lysed by ADCC indicating that the 
effector cells were not permanently inactivated by interac- 
tion with the HLA-bearing targets. Again, this is in con- 
trast  to results with Ly49 + murine NK cdls which were 
also incapable of mediating ADCC against H-2D d bearing 
targets (43). 
Analysis of NK cells clones from donors of a defined HLA 
haplotype has indicated that expression of sdf MHC alleles 
is not necessary to protect a target cell from lysis.  In fact, 
the general conclusion was that alleles with strong protec- 
tive behavior (e.g., HLA-B*5801,  -B'3701) provided resis- 
tance against NK dones from three independent donors of 
unrelated haplotype, none of which expressed HLA-B*5801 
or -B'3701,  Conversely, there was no evidence for perma- 
nent dimination or "donal deletion" of NK clones that were 
potentially reactive with self MHC alleles (although we cannot 
exclude the possibility that the presence of HLA molecules 
might modulate expression of NK cell receptors for sdf HLA 
in vivo, similar to the situation with Ly 49 expression in mu- 
rine allogeneic bone marrow chimeras) (51).  For example, 
the majority of our NK clones failed to lyse HLA-B*5801 
transfectants of C1R or 721.221, irrespective of whether this 
represented an autologous or allogeneic antigen. HLA-A*0201 
rarely protected targets from lysis by NK clones obtained ei- 
ther from donors who expressed HLA-A*0201 (i.e., donors 
315 or 186) or from donors who lacked this allele (i.e., donors 
287 and 288). These findings are in contrast to the observa- 
tion of Karlhofer et al. (43) who have reported the paradox- 
ical observation that murine NK cells bearing Ly49 are not 
present in mice expressing the putative ligand for Ly49, i.e., 
H-2D a. In man, sdf aUdes were able to provide protection 
against certain NK clones, as illustrated by the fact that 48% 
of NK clones from donor 315 were unresponsive to 721.221 
transfected with  HLA-Cw*0301,  a  self allele.  Likewise, 
~73%  of NK clones from donor 186 failed to lyse B-LCL 
transfectants expressing the self allele HLA-B*5801.  Although 
self HLA alleles were protective, there was no apparent in- 
crease in the frequency of NK clones that recognized self HLA 
alleles compared to allogeneic HLA alleles, suggesting that 
"positive selection" for self alleles is unlikely. 
Conclusions derived from our studies of the HLA specificity 
of NK clones contrast in several aspects with the reports of 
Ciccone, Moretta, and co-workers (46, 52-57) and Colonna 
and colleagues (58).  These investigators have reported that 
NK clones can be readily placed into homogeneous groups 
that demonstrate exquisite target cell specificity,  with sus- 
ceptibility to lysis correlating with specific HLA-C alleles 
(54-58). By contrast, our findings indicate that NK clones 
can recognize HLA-A, HLA-B,  and HLA-C antigens and 
that a single NK clone has the potential to recognize mul- 
tiple alleles. However, there are several important differences 
in our experimental approach that might account for these 
discrepancies. It should be appreciated that Ciccone et al. (56) 
have indicated that the data presented to support the exis- 
tence of NK clones with defined specificity represent only 
36% of NK clones examined, leaving 64% of all NK clones 
unaccounted.  By contrast,  in  the present  study,  we have 
presented the experimental findings obtained with all NK 
clones examined from several independent donors to give a 
more comprehensive representation of the total NK cell reper- 
toire of HLA specificity. 
While in our studies HLA-transfected B-LCL were ana- 
lyzed, most of Ciccone, Moretta, and co-workers' experiments 
were performed using PHA lymphoblasts as targets (52-57). 
Presumably PHA lymphoblasts express both alleles of the 
HLA-A, B, and -C genes. Therefore, to identify an NK clone 
with specificity for a single HLA-C allele, all four HLA-A 
and B  antigens  present  on the PHA blast  must  have no 
influence on that NK clone. Our results using HLA trans- 
fected B-LCL, as well as the prior studies of Storkus et al. 
(8-10), Shimizu and DeMars (11), and Kaufman et al. (44, 
59) collectively support the conclusion that most NK cells 
can also recognize HLA-A or HLA-B antigens. Our present 
findings demonstrate that HLA-B*3701, -B'5101,  and -B'5801 
are recognized by >50% of all NK clones from several donors, 
irrespective of whether these alleles  are autologous or al- 
togeneic. Therefore, it is quite surprising that only an HLA-C 
effect was observed when PHA lymphoblasts were used as 
targets, since these targets also express a heterogeneous array 
of HLA-A and -B alleles. We have attempted to use PHA 
lymphoblasts as target cells for a direct comparison with the 
HLA transfected B-LCL. In agreement with Ciccone, Moretta, 
and co-workers we have observed that 48-h PHA lympho- 
blasts from certain donors are susceptible to lysis by certain 
NK clones, whereas lymphoblasts from other donors are resis- 
tant. However, we have noted that when susceptible PHA 
lymphoblasts are maintained in culture for longer time periods 
they very frequently convert from susceptible to totally resis- 
tant to lysis by the same NK clone (Phillips,  J. H., unpub- 
lished observation). Since these resistant PHA lymphoblasts 
still express high levels of HLA antigens on the cell surface, 
unidentified variables other than HLA are undoubtedly respon- 
sible for this phenomenon. Moreover, we have also observed 
that certain NK clones can lyse autologous PHA lympho- 
blasts (Phillips, J. H., unpublished observation). As a conse- 
quence of these findings, together with the complication that 
PHA lymphoblasts potentially express six different HLA al- 
leles, we have focused our studies on the analysis of stable 
HLA transfectants in B-LCL. The only transfectants used in 
Ciccone, Moretta, and co-workers' studies were HLA trans- 
fectants of a murine mastocytoma cell line P815 (56).  One 
1333  Litwin et al. group of NK clones with reactivity against NK "specificity 
2" were unable to lyse routine P815 mastocytoma cell targets 
transfected with  HLA-Cw*0301  (56).  However,  in these 
studies a more extensive analysis of self or non-sdf HLA al- 
1des was not available for comparison, particularly with trans- 
fectants expressing allogeneic or autologous HLA-B alldes. 
In our experience, P815 cells are frequently resistant to lysis 
by  NK  clones without  transfection  with  HLA  (Phillips, 
J. H., unpublished observation). Nonetheless, the general con- 
clusion that NK clones demonstrate the potential to recog- 
nize certain HLA molecules with resulting inhibition of target 
lysis are in accordance with findings of Ciccone, Moretta, 
and co-workers.  In part,  discrepancies in our results could 
be due to the complexity of HLA polymorphism in man. 
Significant individual variation with respect to the behavior 
of NK clones isolated from different donors might be ex- 
pected and in fact has been noted in our study. 
With respect to specificity of different HLA gene prod- 
ucts, our results are more compatible with the conclusions 
of Shimizu and DeMars (11) and Storkus et al. (9) who ana- 
lyzed freshly isolated, resting NK cells for the ability to lyse 
MHC class I-deficient B-I.CL and HLA transfectants. Both 
groups concluded that HLA-A*0201 provided little protec- 
tion and Shimizu and DeMars (11) noted that HLA-B alldes 
were generally more protective than HLA-A alleles in pro- 
viding target protection. Our studies support both of these 
conclusions and are based on analysis of more than 200 in- 
dividual NK clones derived from four donors of different 
haplotypes. However, several of our findings differ from those 
obtained in the earlier studies. First, we have noted that freshly 
isolated polyclonal NK cells from many individuals do not 
lyse the C1R cell line and in some cases do not lyse 721.221, 
whereas K562 was always efficiently lysed by these effector 
cells (our own unpublished observation). Therefore, individual 
variation apparently exists with respect to the ability of freshly 
isolated NK cells to lyse these MHC class I-deficient B-LCL 
targets.  Additionally,  Storkus  et  al.  (8-10)  reported  that 
the HLA-A'0201  allele was not protective against NK cell 
lysis, whereas all other alleles tested (HLA-A*0301, -A'6801, 
-A'6901,  -B*0702,  -B'2705,  -B'5801)  were protective.  In 
addition, the conversion of residue 74, His, in HLA-A*0201 
to Asp, found in HLA-A*0301, -A'6801, -A'6901, -B*0702, 
and -B'2705, reversed the nonprotective phenotype of HLA- 
A'0201 (10). However, in our analysis of NK clones the HLA- 
A2/A28  family alleles  represented in our target  cell panel 
(HLA-A*0201, -A'6801, -A'6901) only infrequently protected 
against NK cell lysis.  By contrast,  members of the HLA- 
A1/A3/All family represented in our target cell panel (HLA- 
A*0101, -A*0301) were protective against ,',,20-30%  of the 
NK clones analyzed. Thus, it appears that members of these 
HLA-A allele families are dissimilar in their ability to pro- 
tecta  target cell from NK cell lysis. 
While expression of MHC class I molecules may certainly 
influence the ability of NK cells to lyse certain targets, other 
MHC-independent mechanisms of NK cell-mediated cyto- 
toxicity apparently exist. We have demonstrated that HLA- 
B'5801 provides substantial protection for EBV-transformed 
B-LCL expressing this allele.  However,  transfection of the 
same allele into the NK-sensitive Jurkat and K562 cell lines 
provided absolutely no protection against lysis by the same 
NK cell clones. Leiden et al. (60) have also reported that trans- 
fection of HLA (A*0201 and B*0702) into NK-sensitive cell 
lines (K562 and MOLT-4) did not alter susceptibility to lysis 
by freshly isolated NK cells.  Similarly, Ly49 + routine NK 
cells efficiently lyse the NK-sensitive YAC-1 T leukemia cell 
line, despite the fact that these cells express the "protective" 
H-2D a allele (43). Possibly the lack of protection of H-2D a 
in YAC-1 and HLA-B*5801 in K562 and Jurkat is due to 
differential presentation of endogenous MHC-associated pep- 
tides in these cell lines. However, given the complexity of 
NK-target cell interactions an equally plausible explanation 
is that multiple NK recognition mechanisms exist, only some 
of which are strictly regulated by MHC dass I expression. 
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